We thank Fernandez-Prado and Ortiz1 for their perspective on the CITRINE study2 of patients with type 2 diabetes and hyperuricemia. They questioned the safety of combining verinurad, a potent urate transporter 1 (URAT1) inhibitor, with the xanthine oxidase (XO) inhibitor febuxostat. They imply that verinurad-treated patients sustained more rapid estimated glomerular filtration rate (eGFR) deterioration and discontinued treatment for excessive loss of eGFR more frequently than with placebo.